Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4562 ARTÍCULOS , VIENDO DEL 1531 AL 1545

Large-Volume Infusions into the Brain: A Comparative Study of Catheter Designs

Brady ML, Raghavan R, Mata J, Wilson M, Wilson S, Odland RM, Broaddus WC.

Stereotact Funct Neurosurg. 2018;96(3):135-141. doi: 10.1159/000488324. Epub 2018 Jul 18.

[Treatment of end-of-dose fluctuations: the need for an individualized approach]

Lingor P, Claßen J, Herbst H, Storch A, Urban P, Wellach I, Jost WH.

Fortschr Neurol Psychiatr. 2018 Sep;86(S 01):S59-S62. doi: 10.1055/a-0583-8460. Epub 2018 Jul 18.

GABA and hallucinations in Parkinson disease: Who is that sitting on my chair?

Onofrj M, Gilbert GJ.

Neurology. 2018 Aug 14;91(7):293-294. doi: 10.1212/WNL.0000000000005985. Epub 2018 Jul 18.

Transient Daily Episodes of Vision Loss Due to Parkinson's Disease

Pelak VS, Berman BD.

Neuroophthalmology. 2018 Jul 20;43(4):260-264. doi: 10.1080/01658107.2018.1494202. eCollection 2019 Aug.

Cell reprogramming approaches in gene- and cell-based therapies for Parkinson's disease

Man JHK, Groenink L, Caiazzo M.

J Control Release. 2018 Sep 28;286:114-124. doi: 10.1016/j.jconrel.2018.07.017. Epub 2018 Jul 17.

Mitochondrial abnormalities in Parkinson's disease and Alzheimer's disease: can mitochondria be targeted therapeutically?

Macdonald R, Barnes K, Hastings C, Mortiboys H.

Biochem Soc Trans. 2018 Aug 20;46(4):891-909. doi: 10.1042/BST20170501. Epub 2018 Jul 19.

Oxidative Stress in Parkinson's Disease: A Systematic Review and Meta-Analysis

Wei Z, Li X, Li X, Liu Q, Cheng Y.

Front Mol Neurosci. 2018 Jul 5;11:236. doi: 10.3389/fnmol.2018.00236. eCollection 2018.

Opioidergic Modulation of Striatal Circuits, Implications in Parkinson's Disease and Levodopa Induced Dyskinesia

Sgroi S, Tonini R.

Front Neurol. 2018 Jul 5;9:524. doi: 10.3389/fneur.2018.00524. eCollection 2018.

Using Directional Deep Brain Stimulation to Co-activate the Subthalamic Nucleus and Zona Incerta for Overlapping Essential Tremor/Parkinson's Disease Symptoms

Falconer RA, Rogers SL, Shenai M.

Front Neurol. 2018 Jul 5;9:544. doi: 10.3389/fneur.2018.00544. eCollection 2018.

Regenerative Therapies for Parkinson's Disease: An Update

Stoker TB, Barker RA.

BioDrugs. 2018 Aug;32(4):357-366. doi: 10.1007/s40259-018-0294-1.

Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease

Mueller C, Rajkumar AP, Wan YM, Velayudhan L, Ffytche D, Chaudhuri KR, Aarsland D.

CNS Drugs. 2018 Jul;32(7):621-635. doi: 10.1007/s40263-018-0540-6.

Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management

Ward KM, Citrome L.

Neurol Ther. 2018 Dec;7(2):233-248. doi: 10.1007/s40120-018-0105-0. Epub 2018 Jul 19.

Mitochondrial dysfunction in protein conformational disorders

Brielle S, Kaganovich D.

J Genet. 2018 Jul;97(3):703-713.

Regulation of membrane dynamics by Parkinson's disease-associated genes

Inoshita T, Cui C, Hattori N, Imai Y.

J Genet. 2018 Jul;97(3):715-725.

Parkinson's disease: what the model systems have taught us so far

Ghatak S, Trudler D, Dolatabadi N, Ambasudhan R.

J Genet. 2018 Jul;97(3):729-751.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias